# A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma

> **NCT05926960** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 38 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** encorafenib
- **DRUG:** binimetinib
- **DRUG:** pembrolizumab
- **DRUG:** ipilimumab
- **DRUG:** nivolumab

## Key facts

- **NCT ID:** NCT05926960
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-06-13
- **Primary completion:** 2026-02-02
- **Final completion:** 2026-02-02
- **Target enrollment:** 38 (ACTUAL)
- **Why stopped:** Study terminated due to inability to recruit the target number of patients. There were no safety and/or efficacy concerns involved in the decision to stop enrollment.
- **Last updated:** 2026-03-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05926960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05926960, "A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05926960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*